Eocene Ltd. (EOCN)
Nasdaq · Healthcare · Biotechnology
$3.45−4.43%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $3.7M
- 52-week range
- $3.12 – $13.20
- 52-week change
- −71.44%
- EPS (trailing)
- −$15.21
Fiscal year to Dec 2025
- Net income
- −$10.3M
- Diluted EPS
- $2.39
From the company’s annual report on SEC EDGAR.
About Eocene Ltd.
Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Eocene Ltd. was formerly known as Galmed Pharmaceuticals Ltd. and changed its name to Eocene Ltd.
Headquarters: Ramat Gan, Israel · 3 employees · eocn.com